Neuropeptide Y (NPY) intranasal delivery alleviates Machado–Joseph disease
Abstract Machado–Joseph disease (MJD) is the most common dominantly-inherited ataxia worldwide with no effective treatment to prevent, stop or alleviate its progression. Neuropeptide Y (NPY) is a neuroprotective agent widely expressed in the mammalian brain. Our previous work showed that NPY overexp...
Saved in:
Main Authors: | Joana Duarte-Neves, Cláudia Cavadas, Luís Pereira de Almeida |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/5e8895de18654bcbb26bcfb30a822f35 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Caloric restriction blocks neuropathology and motor deficits in Machado–Joseph disease mouse models through SIRT1 pathway
by: Janete Cunha-Santos, et al.
Published: (2016) -
Ataxia espinocerebelosa tipo 3 (enfermedad de Machado-Joseph) y vareniclina
by: Young,Pablo, et al.
Published: (2015) -
Diagnóstico de Ataxia Espinocerebelosa tipo 3 (Enfermedad de Machado-Joseph) en Chile
by: Miranda C.,Marcelo
Published: (2015) -
Intranasal Delivery of Nerve Growth Factor in Neurodegenerative Diseases and Neurotrauma
by: Luigi Manni, et al.
Published: (2021) -
Intranasal Delivery of miR-155-5p Antagomir Alleviates Acute Seizures Likely by Inhibiting Hippocampal Inflammation
by: Zhou X, et al.
Published: (2020)